In a report issued on April 29, Pito Chickering from Deutsche Bank maintained a Buy rating on Baxter International (BAX), with a price target of $99.00. The company’s shares closed last Friday at $85.69.
According to TipRanks.com, Chickering is a 4-star analyst with an average return of 19.1% and a 64.9% success rate. Chickering covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, ACADIA Pharmaceuticals, and Option Care Health.
Currently, the analyst consensus on Baxter International is a Strong Buy with an average price target of $95.30, representing an 11.3% upside. In a report issued on April 29, Stifel Nicolaus also maintained a Buy rating on the stock with a $95.00 price target.
See today’s analyst top recommended stocks >>
Based on Baxter International’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.18 billion and net profit of $168 million. In comparison, last year the company earned revenue of $3.04 billion and had a GAAP net loss of $23 million.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BAX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1931 and based in Illinois, Baxter International, Inc. provides a portfolio of healthcare products. The company focuses on transformative innovation to deliver smarter, more personalized care for patients and providers. It operates through six global businesses: Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery and Acute Therapies.